Frontlight ResearchEarly access
Taking peoplePhase 3
A Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction Patients
Key facts
- Who runs it
- Hanmi Pharmaceutical Company Limited
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 225 people, planned
- Started
- Oct 2026
- Expected to end
- Sept 2027
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- HIP2602 + HPP2602-2
- HPP2602-1 + HPP2602-2
- HGP1201 + HPP2602-1
- Record updated
- 27 October 2026
Who can take part
- Age
- 19 years to 75 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Visit 1 (screening)
- Male subjects aged 19 to 75 years, inclusive
- Subjects with a history of erectile dysfunction for at least 3 months prior to Visit 1
- Subjects who are expected to have sexual intercourse with the same adult female partner throughout the study period
- Subjects who agree to attempt sexual intercourse at least 4 times on 4 separate days during the run-in period; Visit 2 (Randomization)
- Subjects with an International Index of Erectile Function (IIEF) Erectile Function (EF) domain score of ≤25 at Visit 2
- Subjects who attempted sexual intercourse at least 4 times on 4 separate days during the run-in period and demonstrated a sexual intercourse failure rate of ≥50%, as assessed by the Sexual Encounter Profile (SEP)
Who cannot take part
- Prior failure to respond to PDE-5 inhibitor therapy
- Use of prohibited concomitant medications or anticipated need for such medications during the study
- Participation in another clinical trial within 30 days prior to Visit 1
- Erectile dysfunction associated with premature ejaculation or endocrine disorders (e.g., hypogonadism, hyperprolactinemia, thyroid disorders)
- History of radical prostatectomy or other pelvic surgery
- Presence of anatomical penile deformity (e.g., Peyronie's disease, penile angulation, cavernosal fibrosis)
- History of major cardiovascular or cerebrovascular disease, including unstable angina, recent myocardial infarction, stroke, uncontrolled arrhythmia, or heart failure
- History of retinitis pigmentosa, NAION, or other hereditary retinal degenerative disorders
- Clinically significant hepatic or renal impairment
- Positive serology for infectious diseases at Visit 1
- Known hypersensitivity to the study drug or its components
- Uncontrolled diabetes mellitus (HbA1c > 10% at Visit 1)
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 19 and 75 years old?
This trial is currently available in South Korea.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A Multicenter, Randomized, Double-blind, Phase Ⅲ Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction Patients
The 3 groups in the trial
- HIP2602 + HPP2602-2Treatment being tested
Daily administration, oral
- HPP2602-1 + HPP2602-2Placebo, for comparison
Daily administration, oral
- HGP1201 + HPP2602-1Other group
Daily administration, oral
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Randomized, Double-blind, Phase Ⅲ Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction Patients
- Criteria questions
- Built from NCT07899073, who can take part
- Record updated
- 27 October 2026